Back to Journals » Degenerative Neurological and Neuromuscular Disease » Volume 1

Evaluation of glycopyrrolate in the treatment of chronic drooling

Authors Reddihough D, Reid, Plover

Published 18 May 2011 Volume 2011:1 Pages 3—7


Review by Single anonymous peer review

Peer reviewer comments 3

DS Reddihough1,2,3, SM Reid2,3, C Plover1
1Royal Children's Hospital, Melbourne, VIC, Australia; 2Murdoch Childrens Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia; 3University of Melbourne, Melbourne, VIC, Australia

Abstract: Drooling is a major problem for children and adults with cerebral palsy and other neurological conditions. Medication is a major treatment option for these individuals. The focus of this review is to review glycopyrrolate, one of the frequently used medications for poor saliva control. Glycopyrrolate is a quaternary ammonium compound structurally related to atropine. The pharmacology, mode of action and pharmocokinetics are discussed, efficacy studies are reviewed, and safety and tolerability are described. Mention is made of the limited amount of information that is available on patient satisfaction and quality of life. Glycopyrrolate has an important place in the treatment of chronic drooling and possible uses for this medication are described. Further research would be helpful comparing glycopyrrolate with other anticholinergic medication and alternative treatments for drooling including botulinum toxins and surgical procedures.

Keywords: dribbling, poor saliva control, cerebral palsy, Parkinson Disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]